cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Tarsus Pharmaceuticals Inc
3 own
4 watching
Current Price
$15.09
$-0.57
(-3.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
402.48M
52-Week High
52-Week High
20.82
52-Week Low
52-Week Low
10.8001
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization402.48M
icon52-Week High20.82
icon52-Week Low10.8001
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Tarsus Pharmaceuticals Inc do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More
How much money does Tarsus Pharmaceuticals Inc make?
News & Events about Tarsus Pharmaceuticals Inc.
Globe Newswire
1month ago
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ...
Globe Newswire
1month ago
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 designed to be an on-demand, long-acting prophylactic treatment that...
Zolmax
3 months ago
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS Get Rating) CFO Leonard M. Greenstein sold 5,000 shares of the businesss stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $15.92, for a total value of $79,600.00. Following the transaction, the chief ...
Globe Newswire
3 months ago
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be presented IRVINE, Calif., Oct. ...
Globe Newswire
4 months ago
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermanns expected transition IRVINE, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (...
Frequently Asked Questions
Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Tarsus Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Tarsus Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Tarsus Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Tarsus Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Tarsus Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Tarsus Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Tarsus Pharmaceuticals Inc?
plus_minus_icon
What percentage is Tarsus Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Tarsus Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$15.09
$-0.57
(-3.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00